Mcrae Capital Management Inc. Has $14.45 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mcrae Capital Management Inc. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 27,769 shares of the medical research company’s stock after acquiring an additional 2,080 shares during the quarter. Thermo Fisher Scientific accounts for about 2.8% of Mcrae Capital Management Inc.’s investment portfolio, making the stock its 16th largest holding. Mcrae Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $14,447,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in TMO. Asset Management One Co. Ltd. boosted its holdings in shares of Thermo Fisher Scientific by 1.3% during the fourth quarter. Asset Management One Co. Ltd. now owns 181,829 shares of the medical research company’s stock worth $95,655,000 after purchasing an additional 2,284 shares during the period. Avestar Capital LLC boosted its stake in shares of Thermo Fisher Scientific by 18.4% during the 4th quarter. Avestar Capital LLC now owns 3,788 shares of the medical research company’s stock valued at $1,971,000 after buying an additional 590 shares during the period. Sawgrass Asset Management LLC grew its holdings in shares of Thermo Fisher Scientific by 2.4% during the 4th quarter. Sawgrass Asset Management LLC now owns 4,040 shares of the medical research company’s stock valued at $2,102,000 after acquiring an additional 96 shares in the last quarter. Phraction Management LLC raised its holdings in shares of Thermo Fisher Scientific by 1.9% during the fourth quarter. Phraction Management LLC now owns 28,127 shares of the medical research company’s stock worth $14,633,000 after acquiring an additional 527 shares in the last quarter. Finally, Ingalls & Snyder LLC boosted its position in Thermo Fisher Scientific by 3.0% during the fourth quarter. Ingalls & Snyder LLC now owns 1,388 shares of the medical research company’s stock valued at $722,000 after purchasing an additional 41 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $532.63 on Friday. The firm has a fifty day moving average price of $548.21 and a two-hundred day moving average price of $571.28. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $203.73 billion, a PE ratio of 32.22, a price-to-earnings-growth ratio of 3.18 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share repurchase plan on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the transaction, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,125 shares of company stock worth $11,231,699. 0.34% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Citigroup raised their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock a “neutral” rating in a research note on Friday, January 31st. Barclays reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Wells Fargo & Company increased their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a report on Friday, January 10th. Finally, Raymond James restated an “outperform” rating and set a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $658.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.